
EquitySector - HealthcareVery High Risk
NAV (27-Oct-25)
Returns (Since Inception)
Fund Size
₹141 Cr
Expense Ratio
0.15%
ISIN
INF109KC1Q72
Minimum SIP
-
Exit Load
-
Inception Date
18 May 2021
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+4.41%
+3.55% (Cat Avg.)
3 Years
+21.61%
+22.90% (Cat Avg.)
Since Inception
+14.64%
— (Cat Avg.)
| Equity | ₹141.32 Cr | 99.98% |
| Others | ₹0.02 Cr | 0.02% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹25.14 Cr | 17.78% |
| Cipla Ltd | Equity | ₹12.65 Cr | 8.95% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹12.4 Cr | 8.77% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹11.2 Cr | 7.92% |
| Dr Reddy's Laboratories Ltd | Equity | ₹11.15 Cr | 7.89% |
| Divi's Laboratories Ltd | Equity | ₹10.81 Cr | 7.65% |
| Fortis Healthcare Ltd | Equity | ₹7.56 Cr | 5.35% |
| Lupin Ltd | Equity | ₹6.92 Cr | 4.89% |
| Torrent Pharmaceuticals Ltd | Equity | ₹5.64 Cr | 3.99% |
| Laurus Labs Ltd | Equity | ₹4.89 Cr | 3.46% |
| Alkem Laboratories Ltd | Equity | ₹4.57 Cr | 3.23% |
| Aurobindo Pharma Ltd | Equity | ₹4.54 Cr | 3.21% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹4.4 Cr | 3.11% |
| Mankind Pharma Ltd | Equity | ₹4.12 Cr | 2.92% |
| Zydus Lifesciences Ltd | Equity | ₹3.67 Cr | 2.60% |
| Biocon Ltd | Equity | ₹3.06 Cr | 2.17% |
| Ipca Laboratories Ltd | Equity | ₹2.78 Cr | 1.97% |
| Abbott India Ltd | Equity | ₹2.28 Cr | 1.62% |
| Piramal Pharma Ltd | Equity | ₹1.77 Cr | 1.25% |
| Syngene International Ltd | Equity | ₹1.77 Cr | 1.25% |
| Net Current Assets | Cash | ₹0.02 Cr | 0.01% |
| Treps | Cash - Repurchase Agreement | ₹0.01 Cr | 0.00% |
Large Cap Stocks
73.36%
Mid Cap Stocks
24.12%
Small Cap Stocks
2.50%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹141.32 Cr | 99.98% |
Standard Deviation
This fund
16.63%
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
0.82
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better
Since May 2021
Since November 2024
ISIN INF109KC1Q72 | Expense Ratio 0.15% | Exit Load - | Fund Size ₹141 Cr | Age 4 years 5 months | Lumpsum Minimum - | Fund Status Open Ended Investment Company | Benchmark NIFTY Healthcare TR TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹10,52,087 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
NAV (27-Oct-25)
Returns (Since Inception)
Fund Size
₹141 Cr
Expense Ratio
0.15%
ISIN
INF109KC1Q72
Minimum SIP
-
Exit Load
-
Inception Date
18 May 2021
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+4.41%
+3.55% (Cat Avg.)
3 Years
+21.61%
+22.90% (Cat Avg.)
Since Inception
+14.64%
— (Cat Avg.)
| Equity | ₹141.32 Cr | 99.98% |
| Others | ₹0.02 Cr | 0.02% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹25.14 Cr | 17.78% |
| Cipla Ltd | Equity | ₹12.65 Cr | 8.95% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹12.4 Cr | 8.77% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹11.2 Cr | 7.92% |
| Dr Reddy's Laboratories Ltd | Equity | ₹11.15 Cr | 7.89% |
| Divi's Laboratories Ltd | Equity | ₹10.81 Cr | 7.65% |
| Fortis Healthcare Ltd | Equity | ₹7.56 Cr | 5.35% |
| Lupin Ltd | Equity | ₹6.92 Cr | 4.89% |
| Torrent Pharmaceuticals Ltd | Equity | ₹5.64 Cr | 3.99% |
| Laurus Labs Ltd | Equity | ₹4.89 Cr | 3.46% |
| Alkem Laboratories Ltd | Equity | ₹4.57 Cr | 3.23% |
| Aurobindo Pharma Ltd | Equity | ₹4.54 Cr | 3.21% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹4.4 Cr | 3.11% |
| Mankind Pharma Ltd | Equity | ₹4.12 Cr | 2.92% |
| Zydus Lifesciences Ltd | Equity | ₹3.67 Cr | 2.60% |
| Biocon Ltd | Equity | ₹3.06 Cr | 2.17% |
| Ipca Laboratories Ltd | Equity | ₹2.78 Cr | 1.97% |
| Abbott India Ltd | Equity | ₹2.28 Cr | 1.62% |
| Piramal Pharma Ltd | Equity | ₹1.77 Cr | 1.25% |
| Syngene International Ltd | Equity | ₹1.77 Cr | 1.25% |
| Net Current Assets | Cash | ₹0.02 Cr | 0.01% |
| Treps | Cash - Repurchase Agreement | ₹0.01 Cr | 0.00% |
Large Cap Stocks
73.36%
Mid Cap Stocks
24.12%
Small Cap Stocks
2.50%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹141.32 Cr | 99.98% |
Standard Deviation
This fund
16.63%
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
0.82
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better
Since May 2021
Since November 2024
ISIN INF109KC1Q72 | Expense Ratio 0.15% | Exit Load - | Fund Size ₹141 Cr | Age 4 years 5 months | Lumpsum Minimum - | Fund Status Open Ended Investment Company | Benchmark NIFTY Healthcare TR TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹10,52,087 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments